1. Home
  2. RVPH vs HTCR Comparison

RVPH vs HTCR Comparison

Compare RVPH & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • HTCR
  • Stock Information
  • Founded
  • RVPH 2006
  • HTCR 2009
  • Country
  • RVPH United States
  • HTCR Japan
  • Employees
  • RVPH N/A
  • HTCR N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • HTCR EDP Services
  • Sector
  • RVPH Health Care
  • HTCR Technology
  • Exchange
  • RVPH Nasdaq
  • HTCR Nasdaq
  • Market Cap
  • RVPH 18.1M
  • HTCR 21.2M
  • IPO Year
  • RVPH N/A
  • HTCR 2022
  • Fundamental
  • Price
  • RVPH $0.57
  • HTCR $0.75
  • Analyst Decision
  • RVPH Strong Buy
  • HTCR
  • Analyst Count
  • RVPH 6
  • HTCR 0
  • Target Price
  • RVPH $4.50
  • HTCR N/A
  • AVG Volume (30 Days)
  • RVPH 19.3M
  • HTCR 2.5M
  • Earning Date
  • RVPH 11-13-2025
  • HTCR 11-13-2025
  • Dividend Yield
  • RVPH N/A
  • HTCR N/A
  • EPS Growth
  • RVPH N/A
  • HTCR N/A
  • EPS
  • RVPH N/A
  • HTCR N/A
  • Revenue
  • RVPH N/A
  • HTCR $29,625,381.00
  • Revenue This Year
  • RVPH N/A
  • HTCR N/A
  • Revenue Next Year
  • RVPH N/A
  • HTCR $3.52
  • P/E Ratio
  • RVPH N/A
  • HTCR N/A
  • Revenue Growth
  • RVPH N/A
  • HTCR 72.95
  • 52 Week Low
  • RVPH $0.25
  • HTCR $0.39
  • 52 Week High
  • RVPH $4.28
  • HTCR $3.38
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 52.50
  • HTCR 44.23
  • Support Level
  • RVPH $0.42
  • HTCR $0.68
  • Resistance Level
  • RVPH $0.69
  • HTCR $0.90
  • Average True Range (ATR)
  • RVPH 0.11
  • HTCR 0.08
  • MACD
  • RVPH -0.02
  • HTCR -0.01
  • Stochastic Oscillator
  • RVPH 32.74
  • HTCR 26.84

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

Share on Social Networks: